All 1 tracked stories fall under one category: fda-approval. Kyoto University is most often covered alongside Jun Takahashi, which appears in 1 of these 1 story. Each carries 3 original sources on average. We currently track 1 Biotech story that mention Kyoto University, all published on March 6, 2026.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Kyoto University
All 1 tracked stories fall under one category: fda-approval. Kyoto University is most often covered alongside Jun Takahashi, which appears in 1 of these 1 story. Each carries 3 original sources on average. We currently track 1 Biotech story that mention Kyoto University, all published on March 6, 2026.
Stories tracked
1
Sources per story
3
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 18 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Kyoto University. Shared-story counts are live from our verified record — not editorial picks.
Japan has officially approved the world's first stem-cell-based treatment for Parkinson's disease, utilizing induced pluripotent stem (iPS) cells. The therapy, developed by Kyoto University and Sumitomo Pharma, marks a historic shift from symptom management to regenerative repair for neurodegenerative disorders.
Kyoto University is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source
link? Report a data issue.